Jason R Stubbs

List of Publications by Year
in descending order

30 papers	1,379 citations	567144 15 h-index	526166 27 g-index
45 all docs	45 docs citations	45 times ranked	2035 citing authors

#	Article	IF	Citations
1	Contribution of phosphate and FGF23 to CKD progression. Current Opinion in Nephrology and Hypertension, 2022, Publish Ahead of Print, .	1.0	2
2	Kidney stone formation in a novel murine model of polycystic kidney disease. American Journal of Physiology - Renal Physiology, 2022, 323, F59-F68.	1.3	3
3	Dietary Interventions Ameliorate Infectious Colitis by Restoring the Microbiome and Promoting Stem Cell Proliferation in Mice. International Journal of Molecular Sciences, 2022, 23, 339.	1.8	9
4	Prognostic Value of Fibroblast Growth Factor 23 in Autosomal Dominant Polycystic Kidney Disease. Kidney International Reports, 2021, 6, 953-961.	0.4	9
5	Response to â€œFibroblast Growth Factor 23 Is a Valuable Predictor of Autosomal Dominant Polycystic Kidney Disease Progressionâ€. Kidney International Reports, 2021, 6, 1482-1483.	0.4	0
6	DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis. Cell Death Discovery, 2021, 7, 169.	2.0	14
7	Dietary phosphate restriction attenuates polycystic kidney disease in mice. American Journal of Physiology - Renal Physiology, 2020, 318, F35-F42.	1.3	16
8	Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD. Kidney360, 2020, 1, 1206-1216.	0.9	10
9	Trimethylamine-<i>N</i>-oxide acutely increases cardiac muscle contractility. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H1272-H1282.	1.5	17
10	Development and validation of a UHPLC-MS/MS method for measurement of a gut-derived uremic toxin panel in human serum: An application in patients with kidney disease. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 618-624.	1.4	24
11	Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease. Scientific Reports, 2019, 9, 15901.	1.6	10
12	Trimethylamine N-Oxide and Cardiovascular Outcomes in Patients with ESKD Receiving Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 261-267.	2.2	48
13	Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD. American Journal of Kidney Diseases, 2018, 71, 27-34.	2.1	46
14	Decreased Kidney Function Is Associated with Enhanced Hepatic Flavin Monooxygenase Activity and Increased Circulating Trimethylamine <i>N</i>-Oxide Concentrations in Mice. Drug Metabolism and Disposition, 2018, 46, 1304-1309.	1.7	23
15	Microbiome and Cardiovascular Disease in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1598-1604.	2.2	47
16	The Acute Inotropic Effect of the Uremic Metabolite, Trimethylamineâ€Nâ€Oxide (TMAO), on Human Cardiac Muscle. FASEB Journal, 2018, 32, 901.11.	0.2	0
17	Cholecalciferol <i>v</i>. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial. British Journal of Nutrition, 2016, 116, 2074-2081.	1.2	22
18	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. Journal of the American Society of Nephrology: JASN, 2016, 27, 305-313.	3.0	323

#	Article	IF	Citations
19	Development and validation of a simple UHPLCâ€"MS/MS method for the simultaneous determination of trimethylamine N-oxide, choline, and betaine in human plasma and urine. Journal of Pharmaceutical and Biomedical Analysis, 2015, 109, 128-135.	1.4	54
20	Decreased Conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 Following Cholecalciferol Therapy in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1965-1973.	2.2	40
21	FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. American Journal of Physiology - Endocrinology and Metabolism, 2014, 307, E426-E436.	1.8	138
22	Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease. Kidney International, 2013, 84, 713-721.	2.6	29
23	Is fibroblast growth factor 23 a harbinger of mortality in CKD?. Pediatric Nephrology, 2012, 27, 697-703.	0.9	11
24	Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. Journal of Bone and Mineral Research, 2012, 27, 38-46.	3.1	92
25	Direct hypertrophic effects of fibroblast growth factor 23 on cardiomyocytes. FASEB Journal, 2012, 26, 1143.4.	0.2	0
26	Does it Matter How Parathyroid Hormone Levels are Suppressed in Secondary Hyperparathyroidism?. Seminars in Dialysis, 2011, 24, 298-306.	0.7	16
27	Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease?. Nephrology News & Issues, 2009, 23, 33-4, 36-7.	0.1	9
28	Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice. Journal of the American Society of Nephrology: JASN, 2007, 18, 2116-2124.	3.0	241
29	PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Role of Fibroblast Growth Factor 23 in Phosphate Homeostasis and Pathogenesis of Disordered Mineral Metabolism in Chronic Kidney Disease. Seminars in Dialysis, 2007, 20, 302-308.	0.7	122
30	Critical Role of Osteopontin in Maintaining Urinary Phosphate Solubility in CKD. Kidney360, 0, 3, 10.34067/KID.0007352021.	0.9	3